Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercepharma.com
FiercePharma
Get the latest updates from FiercePharma directly as they happen.
Follow now 404 followers
Latest posts
Last updated about 1 hour ago
Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data
about 1 hour ago
In patients with BTK-pretreated chronic lymphocytic leukemia, AbbVie and Roche’s Venclexta is...
CMS proposes permanent framework for Medicare drug price negotiations
2 days ago
The Trump administration is floating a proposal to establish a permanent framework...
EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage
2 days ago
J&J's MonumenTAL-3 phase 3 study of bispecific antibody Talvey and Darzalex Faspro...
ASCO 2026 showed that precision oncology’s next challenge is translation
3 days ago
ASCO 2026 highlighted a new reality: precision oncology’s future depends not only...
The legacy approach to real-world data is costing you
3 days ago
Life sciences teams are sourcing and managing data with a hidden cost...
FDA hearing on Amgen's Tavneos will include findings from an independent review
3 days ago
An independent research firm is reviewing data on Amgen’s Tavneos as the...
In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
3 days ago
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer drug Zepzelca...
Lilly, Biogen, Eisai and Genentech sponsor new ‘Let’s Talk Alzheimer’s’ podcast
3 days ago
Audio is becoming an increasingly important area of focus in pharma marketing...
Fierce Pharma Asia—Astellas CEO’s 5-year plan; Takeda’s psoriasis win; RA’s China bridge program
3 days ago
Astellas CEO explained to Fierce the company's new five-year plan. A Takeda...
European Commission Approves CinnaGen’s Zandoriah® (teriparatide biosimilar) for Osteoporosis in Adults
3 days ago
Zandoriah® becomes CinnaGen’s first EU-authorised medicine, reflecting years of investment in infrastructure...
‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff
4 days ago
Staring down a $6 billion patent cliff for its prostate cancer drug...
How lab data powers precision commercialization to drive therapy adoption
4 days ago
Drug commercialization depends on reaching the right physicians at the right moment.